Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | CYP1A1 | P04798 | 6/20 | 0.43 |
| ▸ | CYP1B1 | Q16678 | 6/20 | 0.43 |
| ▸ | CA1 | P00915 | 3/20 | 0.42 |
| ▸ | CA2 | P00918 | 3/20 | 0.42 |
| ▸ | CA12 | O43570 | 2/20 | 0.42 |
| ▸ | CA7 | P43166 | 2/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.39 |
| ▸ | CYP2E1 | P05181 | 2/20 | 0.39 |
| ▸ | CYP2C8 | P10632 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
| ▸ | CYP4B1 | P13584 | 2/20 | 0.39 |
| ▸ | CYP2B6 | P20813 | 2/20 | 0.39 |
| ▸ | CYP3A5 | P20815 | 2/20 | 0.39 |
| ▸ | CYP2A7 | P20853 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL202288 | 0.94 | ALDH1A1 (0.69) | ALDH1A1CYP1A1CYP1B1CA1CA2 | |
| SCHEMBL2999328 | 0.91 | ALDH1A1 (0.65) | ALDH1A1CYP1A1CYP1B1CA1CA2 | |
| SCHEMBL3966378 | 0.91 | ALDH1A1 (0.65) | ALDH1A1CYP1A1CYP1B1CA1CA2 | |
| SCHEMBL15641765 | 0.86 | CYP1A1 (0.50) | ALDH1A1CYP1A1CYP1B1CYP3A4CYP1A2 | |
| SCHEMBL388060 | 0.84 | ALDH1A1 (0.48) | ALDH1A1CYP1A1CYP1B1CA1CA2 | |
| SCHEMBL29427076 | 0.84 | ALDH1A1 (0.48) | ALDH1A1CYP1A1CYP1B1CA1CA2 | |
| SCHEMBL422650 | 0.82 | CYP3A4 (0.50) | ALDH1A1CYP1A1CYP1B1CA1CA2 | |
| SCHEMBL17203652 | 0.82 | ALDH1A1 (0.46) | ALDH1A1CYP1A1CYP1B1CA1CA2 | |
| SCHEMBL14788171 | 0.82 | ALDH1A1 (0.52) | ALDH1A1CYP1A1CYP1B1CYP3A4CYP1A2 | |
| SCHEMBL1710751 | 0.82 | ALDH1A1 (0.46) | ALDH1A1CYP1A1CYP1B1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 364 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119574738-A | Method for detecting related substances in trimethylphloroglucinol | 河北广祥制药有限公司 | 2025-03-07 | — | — | CN | claimed |
| CN-116554378-A | Non-metallocene catalyst, preparation method and application | 万华化学集团股份有限公司 | 2023-08-08 | — | — | CN | claimed |
| CN-114773614-A | Bimetal controllable distribution supramolecular material and preparation method thereof | 吉林大学 | 2022-07-22 | — | — | CN | claimed |
| CN-103193784-B | A kind of containing pyrimidine group rigidity Conjugate macrocycle compound and its preparation method and application | DONGHUA UNIVERSITY (CN) | 2015-10-28 | — | — | CN | claimed |
| US-12637483-B2 | Fused polycyclic compound and light emitting device including the same | SAMSUNG DISPLAY CO., LTD. (KR) | 2026-05-26 | — | — | US | disclosed |
| US-12606741-B2 | Compound, light-emitting device, light-emitting apparatus, electronic device, and lighting device | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2026-04-21 | — | — | US | disclosed |
| US-12588411-B2 | Organic electroluminescence device and fused polycyclic compound for organic electroluminescence device | SAMSUNG DISPLAY CO., LTD. (KR) | 2026-03-24 | — | — | US | disclosed |
| US-12426499-B2 | Organic electroluminescence device and fused polycyclic compound for organic electroluminescence device | SAMSUNG DISPLAY CO., LTD. (KR) | 2025-09-23 | — | — | US | disclosed |
| EP-4108667-B1 | POLYCYCLIC AROMATIC DERIVATIVE COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE USING SAME | SFC CO LTD (KR) | 2025-08-13 | — | — | EP | disclosed |
| US-20250179075-A1 | MK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-06-05 | — | — | US | disclosed |
| US-20250161271-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING CANCER, COMPRISING ANTICANCER AGENT AND NOVEL COMPOUND HAVING INHIBITORY ACTIVITY WITH RESPECT TO PROSTAGLANDIN E2 RECEPTORS | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2025-05-22 | — | — | US | disclosed |
| CN-119638755-A | Binuclear ruthenium pyridine coordination supermolecule self-assembled compound, and preparation method and application thereof | 江苏师范大学 | 2025-03-18 | — | — | CN | disclosed |
| EP-0650476-B1 | PERIPHERAL VASODILATING AGENT CONTAINING N-ACYLATED 4-AMINO PIPERIDINE DERIVATIVES AS ACTIVE INGREDIENTS | OTSUKA PHARMA CO LTD (JP) | 2002-06-26 | — | — | EP | disclosed |
| US-6136826-A | AMINOPIPERIDINE COMPOUNDS SUBSTITUTED WITH ALKANOYL | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2000-10-24 | — | — | US | disclosed |
| US-5760058-A | Peripheral vasodilating agent containing piperidine derivative as active ingredient | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1998-06-02 | — | — | US | disclosed |
| US-5656642-A | Peripheral vasodilating agent containing piperidine derivative as active ingredient | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1997-08-12 | — | — | US | disclosed |
| EP-0650476-A1 | PERIPHERAL VASODILATING AGENT CONTAINING N-ACYLATED 4-AMINO PIPERIDINE DERIVATIVES AS ACTIVE INGREDIENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1995-05-03 | — | — | EP | disclosed |
| WO-1994022826-A1 | PERIPHERAL VASODILATING AGENT CONTAINING N-ACYLATED 4-AMINO PIPERIDINE DERIVATIVES AS ACTIVE INGREDIENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1994-10-13 | — | — | WO | disclosed |
| US-4135045-A | PROCESS FOR POLYMERIZATION OF OLEFINS AND CATALYST COMPOSITION THEREFOR | MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) | 1979-01-16 | — | — | US | disclosed |
| US-4048415-A | TITANIUM-ALUMINUM COORDINATION CATALYSTS | MITSUI PETROCHEMICAL INDUSTRIES LTD. (JA) | 1977-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12606741-B2 | Compound, light-emitting device, light-emitting apparatus, electronic device, and lighting device | CRY1, CRY2, CYBA | ALDH1A1 21/4885CYP1A1 8/4885CYP1B1 9/4885 |
| US-12637483-B2 | Fused polycyclic compound and light emitting device including the same | ESR2, EMC2, CRY2 | ALDH1A1 755/4885CYP1A1 165/4885CYP1B1 126/4885 |
| US-20250161271-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING CANCER, COMPRISING ANTICANCER AGENT AND NOVEL COMPOUND HAVING INHIBITORY ACTIVITY WITH RESPECT TO PROSTAGLANDIN E2 RECEPTORS | PTGES2, PTGIR, PTGES | ALDH1A1 613/4885CYP1A1 672/4885CYP1B1 1218/4885 |
| US-12588411-B2 | Organic electroluminescence device and fused polycyclic compound for organic electroluminescence device | LEF1, CCNL2, LAS1L | ALDH1A1 429/4885CYP1A1 205/4885CYP1B1 360/4885 |
| US-20250179075-A1 | MK2 DEGRADERS AND USES THEREOF | MKNK2, MKRN3, DUS2 | ALDH1A1 2904/4885CYP1A1 1580/4885CYP1B1 963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.